Behçet's syndrome: one year in review 2025

Le résumé fourni par la source

Behçet's syndrome (BS) is a variablevessel vasculitis with multiorgan involvement and heterogeneous clinical manifestations.A list of studies were published on BS last year including studies that explore the epidemiology of BS in different parts of the world, role of potential immunological biomarkers in major organ involvement phenotypes, genome wide association studies, studies on micro RNAs, toll like receptors, neutrophil function and epigenetics that added to our understanding of the pathogenesis, studies on imaging and clinical findings that aim to improve diagnosis, differential diagnosis, and monitoring of each organ involvement, as well as studies on management, especially focusing on the role of TNF inhibitors compared to conventional immunosuppressives.The aim of this review is to provide a critical digest of the studies on BS published during 2024. EpidemiologyBehçet's syndrome (BS) commonly starts early during the second or third decade and the first manifestation is usually oral ulceration.Men display more severe disease with increased frequency of eye, vascular and nervous system involvement and a worse prognosis.Late onset BS, that is defined as onset of symptoms after the age of 40 is less frequent and may show clinical and prognostic differences.A recent systematic review explored the disease characteristics and frequency of such patients (1).The authors identified a total of 13 cohorts reporting on late onset patients from Turkey, Greece, Iran, Lebanon, Israel, Algeria, Tunisia, Morocco, Korea, China, and Taiwan.Among the 8524 patients in these cohorts 7% had late-onset BS and 56% of them were men.Interestingly, there was no difference between men and women

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.